We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Rapid Urine Test Detects Bacteria Causing Pneumonia

By LabMedica International staff writers
Posted on 28 Sep 2014
Print article
The BinaxNOW Streptococcus pneumoniae Antigen Card Test
The BinaxNOW Streptococcus pneumoniae Antigen Card Test (Photo courtesy of Abbott Rapid Diagnostics)
A simple, quick, first-of-a-kind urine test for detecting Streptococcus pneumoniae, one of the bacteria that are a leading cause of pneumonia, can also be used with cerebral spinal fluid (CSF) of patients with meningitis.

The aim of the test is to rule in S. pneumoniae as the probable cause of the pneumonia and the test results can enable a probable diagnosis to be made quicker so treatment can be started sooner with the appropriate antibiotics to combat the S. pneumoniae.

To do the test, a swab is dipped into a urine specimen, removed and inserted into a special test device. The test detects S. pneumoniae antigen in the urine of infected patients within 15 minutes. A positive result indicates that the patient most likely has pneumococcal pneumonia. Results should be confirmed with laboratory culture of the bacteria.

Conventional methods for diagnosing pneumonia, primarily using sputum or blood, are lengthy and require from two to three days up to several weeks. These conventional tests are often complex and the results are not always reliable. The new test, called Alere BinaxNOW Streptococcus pneumoniae Antigen Card (Binax, Inc.; Portland, ME, USA) is much quicker, more reliable and easier to use.

The Binax test was found to be 93% accurate in detecting S. pneumoniae when it was performed on urine samples from 373 patients known to have pneumococcal pneumonia. It was 78% accurate when performed on urine from 215 patients who had typical symptoms of pneumonia, but may not have had the disease. However, test results were not reliable in people who had been vaccinated for pneumonia within the past five days. The urine test’s sensitivity was 86% and specificity was 94%, while for CSF samples the sensitivity was 97% and specificity 99%.

It is often very difficult to distinguish between a respiratory infection that is caused by a virus and one which is caused by a bacterium and this is critical distinction because a viral infection will not respond to the commonly used antibiotics whereas a bacterial infection usually will. The Binax test can help in detecting the bacterium S. pneumoniae but it does not detect other bacteria nor does it detect viruses capable of causing pneumonia.

Related Links:

Binax, Inc. 


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Benchtop Cooler
PCR-Cooler & PCR-Rack
New
TRAb Immunoassay
Chorus TRAb
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.